Diranersen showed robust tau reduction and cognitive benefits in early Alzheimer's, with the 60 mg twice-yearly dose emerging as optimal. Safety was favorable, and high patient retention supports advancing to phase III, with long-term data and further regulatory engagement planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.